Comment on

• Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.

  Westergaard LG, Laursen SB, Andersen CY. Westergaard LG, et al. Hum Reprod. 2000 May;15(5):1003-8. doi: 10.1093/humrep/15.5.1003. Hum Reprod. 2000. PMID: 10783342
• Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.

  Borm G, Mannaerts B. Borm G, et al. Hum Reprod. 2000 Jul;15(7):1490-8. doi: 10.1093/humrep/15.7.1490. Hum Reprod. 2000. PMID: 10875855 Clinical Trial.
• Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.

  European and Middle East Orgalutran Study Group. European and Middle East Orgalutran Study Group. Hum Reprod. 2001 Apr;16(4):644-51. doi: 10.1093/humrep/16.4.644. Hum Reprod. 2001. PMID: 11278211 Clinical Trial.